| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd5aa8caf72702076c71578e5434e69f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f95622ccd81207313deed9281820a9b4 |
| publicationDate |
2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020371103-A1 |
| titleOfInvention |
Precision Medicine Method for Cancer Immunotherapy |
| abstract |
Cancer immunotherapy has achieved immense clinical success with long survival even in the most difficult to treat cancer. Yet this effect is only observed in a minority and there are no biomarkers of this response. The methods described herein improve cancer immunotherapy outcomes using two independent measures of systemic chronic inflammation (the inflammatory age—iAge—and cytokine response score—CRS) to stratify cancer patients into responders versus non-responders to cancer immunotherapy. The iAge personalized immune proteome signature creates an individualized initial therapy to reduce iAge and to convert non-responders patients into responders prior to treatment. Nonresponders can be converted to responders by treating the patients to reduce their iAge and improve their CRS. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023027951-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023038858-A1 |
| priorityDate |
2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |